NEW YORK – OpGen announced on Wednesday preliminary fourth quarter revenue of $1.3 million, up nearly 63 percent compared to the previous year.
The infectious disease diagnostics firm, however, noted that preliminary fiscal year 2020 revenue was $5.2 million, down 13 percent from $6.0 million in 2019. OpGen's cash position was $13.3 million as of the end of 2020.